Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California (NASDAQ:PACB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership.

Is PACB or QTRX more profitable?

Quanterix has a net margin of -30.71% compared to Pacific Biosciences of California's net margin of -211.99%. Quanterix's return on equity of -11.52% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-211.99%	-40.98%	-15.65%
Quanterix	-30.71%	-11.52%	-9.47%

Do analysts prefer PACB or QTRX?

Pacific Biosciences of California presently has a consensus target price of $4.50, suggesting a potential upside of 161.63%. Quanterix has a consensus target price of $23.00, suggesting a potential upside of 93.28%. Given Pacific Biosciences of California's higher probable upside, equities analysts plainly believe Pacific Biosciences of California is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	0 Sell rating(s)	7 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.53
Quanterix	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has preferable valuation and earnings, PACB or QTRX?

Quanterix has lower revenue, but higher earnings than Pacific Biosciences of California. Quanterix is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$188.87M	2.48	-$306.73M	-$1.14	-1.51
Quanterix	$122.37M	3.73	-$32.33M	-$0.96	-12.40

Does the MarketBeat Community prefer PACB or QTRX?

Pacific Biosciences of California received 180 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 67.22% of users gave Pacific Biosciences of California an outperform vote while only 61.70% of users gave Quanterix an outperform vote.

Company	Underperform	Outperform
Pacific Biosciences of California	Outperform Votes 449 67.22%	Underperform Votes 219 32.78%
Quanterix	Outperform Votes 269 61.70%	Underperform Votes 167 38.30%

Do institutionals & insiders have more ownership in PACB or QTRX?

86.5% of Quanterix shares are owned by institutional investors. 1.9% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 6.9% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has more volatility & risk, PACB or QTRX?

Pacific Biosciences of California has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Does the media favor PACB or QTRX?

In the previous week, Pacific Biosciences of California and Pacific Biosciences of California both had 3 articles in the media. Quanterix's average media sentiment score of 0.35 beat Pacific Biosciences of California's score of 0.18 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quanterix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Quanterix beats Pacific Biosciences of California on 10 of the 17 factors compared between the two stocks.